Agency for Healthcare Research and Quality

In the Wake of a New Report on Diagnostic Errors, Society to Improve Diagnosis in Medicine (SIDM) Invites Collaboration and Policy Action

Retrieved on: 
Monday, December 19, 2022
Woman, Agency, National academy, SIDM, AHRQ, Diagnosis, Society, Gordon, Partnership, Health, Patient safety, Congress, Learning, Total permanent disability insurance, Emergency, Education, Doctor of Philosophy, Emergency department, Systematic review, Government, Patient, John A. Hartford Foundation, Johns Hopkins University, Risk, Death, National Academies of Sciences, Engineering, and Medicine, Coalition, Policy, Agency for Healthcare Research and Quality, MPH, Medical device, Pharmaceutical industry, Medicine, MD, Engineering

With the support of the Gordon and Betty Moore Foundation, the John A. Hartford Foundation, and other partners and stakeholders, SIDM continues to work to elevate and bring awareness to the issue of diagnosis--the entry point of the patient's care pathway. If the diagnosis is inaccurate or delayed, all else that follows may be harmful, wasteful, or both. SIDM invites everyone involved in the healthcare ecosystem to join us in pursuing education, novel technology solutions, standardized measurement, focused training, and better feedback systems. In addition, we can improve workstreams for greater patient safety, reporting methods, and innovative performance monitoring. Increased teamwork and improved strategies that include patient engagement are essential.

Key Points: 
  • Furthermore, the report found that women and people of color are 20 to 30 percent more likely to be misdiagnosed.
  • The Society to Improve Diagnosis in Medicine (SIDM) believes there is hope for alleviating risk and achieving excellence in diagnosis.
  • The Society to Improve Diagnosis in Medicine catalyzes and leads change to improve diagnosis and eliminate harm from diagnostic error.
  • In 2015, SIDM established the Coalition to Improve Diagnosis to increase awareness and actions that improve diagnosis.

Share of Patients with Heat Exhaustion Increased 53 Percent When Comparing June 2016 to June 2021, according to New FAIR Health Study

Retrieved on: 
Tuesday, December 13, 2022
CMS, Heat, Certification, Agency for Healthcare Research and Quality, Centers for Medicare & Medicaid Services, AHRQ, Agency, Government, Diagnosis, Patient, HITRUST, Collection, Kiplinger, Research, Hospital, FAIR, Health, Policy, News, AICPA, The Price, URAC, Heat exhaustion, Medicare Part D, Personal finance, Database, Climate change, Medicare, PIP, Health insurance, Medicine

NEW YORK, Dec. 13, 2022 /PRNewswire/ -- Among privately insured individuals receiving medical services, the percentage of patients diagnosed with heat exhaustion increased 52.5 percent when comparing June 2016 to June 2021. This was part of a general trend in which, from May to September, the percentage of patients who were diagnosed with heat stress, heat exhaustion or heatstroke was higher in each month in 2021 than in the corresponding month of 2016. These and other findings are reported in a FAIR Health brief released today, Heat-Related Illness: A Window into Recent Trends.

Key Points: 
  • These and other findings are reported in a FAIR Health brief released today, Heat-Related Illness: A Window into Recent Trends .
  • Three types of heat-related illnessin order of increasing severity, heat stress, heat exhaustion and heatstrokewere examined in the period from May through September for the years 2016-2021.
  • Changes in percent of patients diagnosed, as well as their age and gender, were studied for each type of illness.
  • The percentage of patients with heat stress, heat exhaustion or heatstroke diagnoses increased with age, with the greatest percentage found in the age group 65 years and older.

New Research Shows Two Cups of Tea a Day May Keep the Doctor Away

Retrieved on: 
Wednesday, December 7, 2022
Online, Drinking, Agency for Healthcare Research and Quality, Dietitian, GA, Medical statistics, National Center for Healthy Housing, MEPS, Centers for Disease Control and Prevention, Doctor of Philosophy, Science, Quality, Academy of Nutrition and Dietetics, Partnership, Research, Advances in Nutrition, 2009 Davis Cup, Meta-analysis, Medical Expenditure Panel Survey, Tea, Area studies, Drink, Nutrient, Disease, U.S.A, Diabetes, Cardiovascular disease, Woman, Multimedia, Diet, Council, Degenerative disease, Cholesterol, Health, Systematic review, North Eastern Tea Association, Blood pressure, Stroke, CDC, National Center for Health Statistics, Risk, Dietary supplement, Coffee, Pharmaceutical industry, Nutrition, Food, Death, RD

NEW YORK, Dec. 7, 2022 /PRNewswire/ -- While scientific evidence has supported the health properties of tea's bioactive compounds, there is now guidance on how much of these nutrients we need to consume for health benefits. New guidelines published in Advances in Nutrition have extrapolated data from published research to form dietary recommendations for flavan-3-ol intake. This research and guidance is the culmination of a collaboration between the Institute for the Advancement of Food and Nutrition Science, an international expert panel and The Academy of Nutrition and Dietetics to release recommendations for specific quantities of flavan-3-ols to consume daily to reap health benefits.

Key Points: 
  • New guidelines published in Advances in Nutrition have extrapolated data from published research to form dietary recommendations for flavan-3-ol intake.
  • Data shows that consumption of 400-600mg of flavan-3-ols daily (about 2 cups of brewed green or black tea) can help improve blood pressure, cholesterol, and blood sugar.
  • Flavan-3-ols are plant compounds found in many foods and drinks, such as tea, berries, craisins, apples, and dark chocolate.
  • Following these guidelines, research suggests health benefits can be seen from consuming about two, eight-ounce cups of green or black tea each day.

Health Evolution Selects Sage Growth Partners to Develop and Launch New Website

Retrieved on: 
Wednesday, December 7, 2022
Partnership, Chicago Growth Partners, Research, Philips, Marketing, SGP, Agency for Healthcare Research and Quality, GE Healthcare, Organization, Management

BALTIMORE, Dec. 7, 2022 /PRNewswire/ -- Sage Growth Partners (SGP), a Baltimore-based healthcare research, strategy, and marketing firm, is proud to announce the launch of a new website for its client Health Evolution.

Key Points: 
  • BALTIMORE, Dec. 7, 2022 /PRNewswire/ -- Sage Growth Partners(SGP), aBaltimore-based healthcare research, strategy, and marketing firm, is proud to announce the launch of a new website for its client Health Evolution .
  • Health Evolution empowers positive change in health care through their curated community of influential chief executives and senior leaders from all sectors of the health care industry.
  • "Sage Growth Partners helped us achieve our goal in launching a well-designed and highly functional website and online presence to foster collaboration among our cross-industry community of health care leaders," said Dan Melore, EVP Marketing and Operations, Health Evolution.
  • Sage Growth Partners serves clients across the full healthcare spectrum, including GE Healthcare, ProgenyHealth, the National Minority Health Association, Philips Healthcare, Livongo, and Syft.

COVID-19 Declined among Top Five Telehealth Diagnoses Nationally and in Most Regions in September 2022

Retrieved on: 
Monday, December 5, 2022
CMS, Certification, Agency for Healthcare Research and Quality, Centers for Medicare & Medicaid Services, AHRQ, Agency, Government, Diagnosis, Patient, HITRUST, Collection, Kiplinger, Hospital, FAIR, Health, CPT, Medicare Advantage, AICPA, News, Medicaid, COVID-19, Map, The Price, URAC, Medicare Part D, Personal finance, Infection, Database, Telehealth, Medicare, PIP, Pharmaceutical industry, Health insurance

NEW YORK, Dec. 5, 2022 /PRNewswire/ -- COVID-19 declined among the top five telehealth diagnoses nationally and in most US census regions from August to September 2022, according to FAIR Health's Monthly Telehealth Regional Tracker. Nationally and in the Midwest, COVID-19 fell from second to third place in the rankings. In the South, it fell from third to fifth place, and in the West, it fell from third place out of the rankings. Only in the Northeast did COVID-19 maintain its position at second place. The data represent the privately insured population, including Medicare Advantage and excluding Medicare Fee-for-Service and Medicaid.

Key Points: 
  • NEW YORK, Dec. 5, 2022 /PRNewswire/ -- COVID-19 declined among the top five telehealth diagnoses nationally and in most US census regions from August to September 2022, according to FAIR Health's Monthly Telehealth Regional Tracker .
  • In addition to the changes involving COVID-19, acute respiratory diseases and infections rose among the top five telehealth diagnoses nationally and in most regions from August to September 2022.
  • The rankings of the top five telehealth specialties did not change nationally or regionally from August to September 2022.
  • For September 2022, the Telehealth Cost Corner spotlighted the cost of CPT 99441, 5-10-minute telephone medical discussion with physician.

Cardiac Troponin Diagnostics Market Growth Boosted by High-sensitivity Point-of-care Testing

Retrieved on: 
Wednesday, November 30, 2022
SAN, ED, Diagnosis, Organization, POCT, Hospital, Patient, Fortune 1000, MI, Traction, EDS, Frost, POC, Biomarker, Myocardial infarction, Length of stay, Point-of-care testing, Troponin, Agency for Healthcare Research and Quality, Research, CTN, Probability, Medical device, Pharmaceutical industry

SAN ANTONIO, Nov. 30, 2022 /PRNewswire/ -- The global demand for cardiac troponin (cTn) diagnostics biomarkers is increasing as more patients with cardiac complaints are visiting emergency departments (EDs), according to Frost & Sullivan's recent analysis of the cTn diagnostics market. The sector is driven by hospitals and clinical laboratories adopting high-sensitivity (hs)-cTn assays, which can detect troponin in lower concentrations and significantly shorten the timeline for myocardial infarction (MI) detection. The global market for cTn diagnostics is expected to reach $2.28 billion by 2025, up from $2.07 billion in 2021, representing a 2.4% compound annual growth rate.

Key Points: 
  • SAN ANTONIO, Nov. 30, 2022 /PRNewswire/ -- The global demand for cardiac troponin (cTn) diagnostics biomarkers is increasing as more patients with cardiac complaints are visiting emergency departments (EDs), according to Frost & Sullivan's recent analysis of the cTn diagnostics market.
  • The global market for cTn diagnostics is expected to reach $2.28 billion by 2025, up from $2.07 billion in 2021, representing a 2.4% compound annual growth rate.
  • Soundankar added: "Point-of-care testing (POCT) is rapidly gaining traction globally and reduces turnaround time and the length of stay in the ED.
  • For over six decades, Frost & Sullivan has helped build sustainable growth strategies for Fortune 1000 companies, governments, and investors.

Cardiac Troponin Diagnostics Market Growth Boosted by High-sensitivity Point-of-care Testing

Retrieved on: 
Wednesday, November 30, 2022
SAN, ED, Diagnosis, Organization, POCT, Hospital, Patient, Fortune 1000, MI, Traction, EDS, Frost, POC, Biomarker, Myocardial infarction, Length of stay, Point-of-care testing, Troponin, Agency for Healthcare Research and Quality, Research, CTN, Probability, Medical device, Pharmaceutical industry

SAN ANTONIO, Nov. 30, 2022 /PRNewswire/ -- The global demand for cardiac troponin (cTn) diagnostics biomarkers is increasing as more patients with cardiac complaints are visiting emergency departments (EDs), according to Frost & Sullivan's recent analysis of the cTn diagnostics market. The sector is driven by hospitals and clinical laboratories adopting high-sensitivity (hs)-cTn assays, which can detect troponin in lower concentrations and significantly shorten the timeline for myocardial infarction (MI) detection. The global market for cTn diagnostics is expected to reach $2.28 billion by 2025, up from $2.07 billion in 2021, representing a 2.4% compound annual growth rate.

Key Points: 
  • SAN ANTONIO, Nov. 30, 2022 /PRNewswire/ -- The global demand for cardiac troponin (cTn) diagnostics biomarkers is increasing as more patients with cardiac complaints are visiting emergency departments (EDs), according to Frost & Sullivan's recent analysis of the cTn diagnostics market.
  • The global market for cTn diagnostics is expected to reach $2.28 billion by 2025, up from $2.07 billion in 2021, representing a 2.4% compound annual growth rate.
  • Soundankar added: "Point-of-care testing (POCT) is rapidly gaining traction globally and reduces turnaround time and the length of stay in the ED.
  • For over six decades, Frost & Sullivan has helped build sustainable growth strategies for Fortune 1000 companies, governments, and investors.

EF Hutton Expands Healthcare Franchise with Appointments of Veteran Equity Research Analysts 

Retrieved on: 
Tuesday, November 29, 2022
Benchmark, Financial Times, Rockefeller Foundation, Research, EF, Biotechnology, Associate, Secondary research, AMA, Doctor of Philosophy, Johns Hopkins University, Wall Street, University of California, AIM, Health, Virginia BioTechnology Research Park, Baylor University, Raymond James Financial, KWG, Engineering, Rockefeller, The Wall Street Journal, University, Roth Capital Partners, Health care, BS, Guggenheim Partners, Rockefeller University, Cantor Fitzgerald, MD, Senior, Materials science, Agency for Healthcare Research and Quality, Lehman, EF Hutton, Pharmaceutical industry, Management, Guggenheim, Neuroscience

New York, NY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --EF Hutton, division of Benchmark Investments LLC (EF Hutton), today announced a series of strategic hires enhancing the companys Healthcare Equity Research Department.

Key Points: 
  • New York, NY, Nov. 29, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire --EF Hutton, division of Benchmark Investments LLC (EF Hutton), today announced a series of strategic hires enhancing the companys Healthcare Equity Research Department.
  • Tony Butler, Senior Managing Director, Elemer Piros, Managing Director, Fozia Ahmed, Associate and Tashdid Hasan, Associate, will join the team of Healthcare Equity Research Analysts at EF Hutton.
  • Joseph T. Rallo, CEO of EF Hutton, stated, Four major healthcare appointments demonstrates that EF Hutton is committed to bringing on top tier talent.
  • Tony Butler, PhD, Senior Managing Director, joins EF Hutton with over 30 years of experience focusing on the pharmaceutical and biotechnology industry.

Digital Technologies Driving Transformational Growth Across the Biomanufacturing Value Chain

Retrieved on: 
Tuesday, November 29, 2022
Growth, SAN, Digitalization, Digital, Organization, CGT, Fortune 1000, Frost, Agency for Healthcare Research and Quality, Vaccine, Medical imaging

SAN ANTONIO, Nov. 29, 2022 /PRNewswire/ -- The biomanufacturing sector is experiencing a digitalization transformation that is aligned with Industry 4.0. According to Frost & Sullivan's recent analysis on the digital biomanufacturing industry, digital tools applied across processes, monitoring, analytics, and operations have accelerated biomanufacturing with a data-driven approach. Some of the most difficult challenges in biomanufacturing are scalability and reproducibility, particularly in the production of biologics and cell and gene therapies. However, digitalization enables a long-term, effective, cost-effective, and error-free biomanufacturing system.

Key Points: 
  • According to Frost & Sullivan's recent analysis on the digital biomanufacturing industry, digital tools applied across processes, monitoring, analytics, and operations have accelerated biomanufacturing with a data-driven approach.
  • "Digitalization improves the entire value chain of manufacturing biologics, competitive generic therapy (CGT) products, and vaccines," said Neeraja Vettekudath, Healthcare Research Analyst at Frost & Sullivan.
  • This increases efficiency, creating growth opportunities for digital biomanufacturing solution providers, enablers, and adopters."
  • To capitalize on the growth prospects of digital biomanufacturing, market participants should:
    Invest in building digital twin models for predictive and data-driven biomanufacturing decisions.

Digital Technologies Driving Transformational Growth Across the Biomanufacturing Value Chain

Retrieved on: 
Tuesday, November 29, 2022
Growth, SAN, Digitalization, Digital, Organization, CGT, Fortune 1000, Frost, Agency for Healthcare Research and Quality, Vaccine, Medical imaging

SAN ANTONIO, Nov. 29, 2022 /PRNewswire/ -- The biomanufacturing sector is experiencing a digitalization transformation that is aligned with Industry 4.0. According to Frost & Sullivan's recent analysis on the digital biomanufacturing industry, digital tools applied across processes, monitoring, analytics, and operations have accelerated biomanufacturing with a data-driven approach. Some of the most difficult challenges in biomanufacturing are scalability and reproducibility, particularly in the production of biologics and cell and gene therapies. However, digitalization enables a long-term, effective, cost-effective, and error-free biomanufacturing system.

Key Points: 
  • According to Frost & Sullivan's recent analysis on the digital biomanufacturing industry, digital tools applied across processes, monitoring, analytics, and operations have accelerated biomanufacturing with a data-driven approach.
  • "Digitalization improves the entire value chain of manufacturing biologics, competitive generic therapy (CGT) products, and vaccines," said Neeraja Vettekudath, Healthcare Research Analyst at Frost & Sullivan.
  • This increases efficiency, creating growth opportunities for digital biomanufacturing solution providers, enablers, and adopters."
  • To capitalize on the growth prospects of digital biomanufacturing, market participants should:
    Invest in building digital twin models for predictive and data-driven biomanufacturing decisions.